Targeting integrin pathways: mechanisms and advances in therapy

X Pang, X He, Z Qiu, H Zhang, R Xie, Z Liu… - … and Targeted Therapy, 2023 - nature.com
Integrins are considered the main cell-adhesion transmembrane receptors that play
multifaceted roles as extracellular matrix (ECM)-cytoskeletal linkers and transducers in …

Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review

JC Kovacic, S Dimmeler, RP Harvey, T Finkel… - Journal of the American …, 2019 - jacc.org
Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell
undergoes a series of molecular events that lead to a change in phenotype toward a …

[PDF][PDF] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

N Galiè, M Humbert, JL Vachiery… - Polish Heart …, 2015 - journals.viamedica.pl
6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Epidemiology and treatment of pulmonary arterial hypertension

EMT Lau, E Giannoulatou, DS Celermajer… - Nature Reviews …, 2017 - nature.com
In the past 2 decades, major changes have occurred in the epidemiological and treatment
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

JDW Evans, B Girerd, D Montani, XJ Wang… - The lancet Respiratory …, 2016 - thelancet.com
Background Mutations in the gene encoding the bone morphogenetic protein receptor type II
(BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH) …

Management of pulmonary arterial hypertension

VV McLaughlin, SJ Shah, R Souza… - Journal of the American …, 2015 - jacc.org
Pulmonary hypertension (PH) is common and may result from a number of disorders,
including left heart disease, lung disease, and chronic thromboembolic disease. Pulmonary …

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European …

N Galie, MM Hoeper, M Humbert, A Torbicki… - European heart …, 2009 - academic.oup.com
Thus, the task of writing Guidelines or Expert Consensus documents covers not only the
integration of the most recent research, but also the creation of educational tools and …

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era

M Humbert, O Sitbon, A Chaouat, M Bertocchi… - Circulation, 2010 - Am Heart Assoc
Background—Novel therapies have recently become available for pulmonary arterial
hypertension. We conducted a study to characterize mortality in a multicenter prospective …

Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases

Y Li, KO Lui, B Zhou - Nature Reviews Cardiology, 2018 - nature.com
Endothelial cells and mesenchymal cells are two different cell types with distinct
morphologies, phenotypes, functions, and gene profiles. Accumulating evidence, notably …

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …

Writing Committee Members, VV McLaughlin… - Circulation, 2009 - Am Heart Assoc
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension | Circulation Science
Volunteer Warning signs SearchSearch Advanced Search Donate Circulation logo Hello Guest …